Clinical trialObservationalUnknown
PAncreas Borderline and Locally Advanced Snapshot Study
- Outcome
- Outcome unknown
- Phase
- Observational
- Status
- Unknown
- Study type
- Observational
- Start
- 15 September 2022
- Listed end
- 15 September 2024
- Enrollment
- 230 participants
- Sites
- 23
- Primary outcomes
- The main study's objective is to definite the effective rate of adjuvant chemotherapy performed after surgery (at the 3-month post operatively), which is essential marker recognized as improving overall survival.
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 22 July 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The project's objective is to carry out prospectively, in France, for one year, a descriptive registry study in the management of patients with borderline or locally advanced pancreatic adenocarcinoma, and to collect both the patient's demographic characteristics, but also the therapeutic regimens applied, the types of surgeries performed and the outcome of the patients after surgery, and at three months of follow up (preoperative data, complications's post surgery, quality of the resection, etc.)
Detailed description public domain (ClinicalTrials.gov)
* Multicenter, observational prospective study over one year in France in patients with borderline or locally advanced pancreatic adenocarcinoma operated between September 2022 and August 2023. * Patients will be screened by the pancreatic's surgeons practicing in a reference centers during preoperative surgical consultations (V1), * The patient's non-objection will be sollected, * The end of follow-up's patient will take place during the post-operative consultation approximately 3 months after surgery (V3) * Between V1 and V3, preoperative data (demography, history, tumor characteristics, neoadjuvant treatments performed, tumor response), operative, intraoperative, pathological and postoperative data will be collected via a e-CRF " the REDCAP software".